Todd Neale

(UPDATED) The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical use.

A caveat to the OPTIMA-AF trial: event rates were much lower than expected, complicating interpretation.

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

Lower-cost cutting and noncompliant balloons were noninferior to Shockwave IVL for short-term stent outcomes.

Experts continue to debate whether the health status benefits are real and enough to justify doing the procedures for severe TR.

Polypills for HFrEF are being tested in RCTs, and if they’re approved, experts want to be ready for their rollout and use.

The findings underscore that pregnancy is “a crucial window of opportunity to optimize cardiovascular health,” researchers say.

In top-line results, the phase III trial demonstrated a “highly clinically meaningful reduction” in 24-hour systolic BP.

The paper aims to increase awareness of cardiac long COVID and make management quicker, more accurate, and safer.

The high cost of semaglutide and other GLP-1 drugs is likely behind many of the discontinuations.